Author Archive

Patient access to innovation: Biopharmaceuticals, 4th hurdles and socioeconomic issues

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Patient access to innovation: Biopharmaceuticals, 4th hurdles and socioeconomic issues
Go to paperABSTRACT: Biopharmaceuticals and innovative therapeutic…


Autoimmune and inflammatory disorder biologicals will power biotech market growth through to 2010

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Autoimmune and inflammatory disorder biologicals will power biotech market growth through to 2010
Go to paperABSTRACT: Biologicals designed to treat arth…


Genetic testing services in Europe: Quality assurance and policy issues

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Genetic testing services in Europe: Quality assurance and policy issues
Go to paperABSTRACT: The popular press is painting a picture of a future in which…


Latest Licensable Biotechnology Inventions

TechTransferWatch is a search engine and alert service for licenseable technologies from academic labs, foundations, and government. Click the patents below for more details, or visit TechTransferWatch.com for more options. Diagnostic assays and methods of use for detection of filarial infection Thomas B. Nutman, Doran Fink, Joseph Kubofcik, Peter D. Burbelo Department of Health and […]


Cannabis-Derived Pharmaceuticals

Cannabis, commonly known as marijuana, weed or pot, is a natural product derived from the Cannabis sativa plant. It has been used medicinally for thousands of years. Recent legislation allowing the use of medical marijuana in over 23 US states has spurred interest in developing pharmaceutical-derived Cannabis products to treat a variety of clinical indications ranging from pain relief to epilepsy.  Many products are in late stage clinical development in the US and elsewhere.  This article reviews the medicinal properties of Cannabis and describes pharmaceutical-derived Cannabis products that are currently being developed for theUS market.

 


BioTime’s bid to end age-related disease: A look at CEO Michael West’s Vision

The regenerative medicine space is one that is set to explode with considerable innovation and profitability for shrewd biotechnologists. I had the opportunity to speak with Michael West, PhD., CEO of BioTime (BTX) and found a man passionate about rege…